Circulating Tumor Cells (CTCs)
Scientists are learning to read the clues that cancer leaves behind in the bloodstream, developing new approaches that may be less invasive and more convenient for patients. A key focus of this emerging field is the study of Circulating Tumor Cells (CTCs).
What are circulating tumor cells?
Breast cancer is a dynamic disease in which cells grow and divide abnormally. In some cases, cancer cells can break away from the primary tumor and enter the lymphatic system or the bloodstream. These cells are known as circulating tumor cells, or CTCs.
CTCs may travel as single cells or as clusters, small groups of tumor cells that remain attached to one another. While single CTCs often struggle to survive in the bloodstream, clusters have a much greater metastatic potential. By staying together, they can employ biological strategies, such as cloaking themselves with platelets or white blood cells, or sending "turn-off" signals to immune cells, allowing them to evade the body's natural defenses.
Why are CTCs important in Metastatic Breast Cancer?
Scientists are interested in CTCs because they may provide valuable clues about how metastatic breast cancer develops, evolves, and adapts over time.
A rising number of CTCs in the bloodstream can provide an early indication of disease progression, suggesting that the cancer is becoming more active. Because these cells can enter the blood long before they form detectable lesions, tracking them may reveal an impending relapse or disease progression before changes become visible on conventional imaging tests such as CT or bone scans. CTCs may also help detect small amounts of residual disease that remain after treatment and could eventually lead to recurrence. Detecting these residual cells through a blood test could offer an opportunity to monitor disease activity when conventional methods are less informative.
CTCs may also provide a broader view of disease than traditional tissue biopsies. While biopsies offer a snapshot from a single tumor site, CTCs can originate from multiple locations, providing a more comprehensive picture of how the cancer is changing over time. This may help researchers and clinicians better understand how cancer is responding to treatment.
How can CTCs be detected?
The ability to study CTCs begins with a liquid biopsy, a simple blood test. Unlike a traditional tissue biopsy, which requires surgery or a needle procedure to sample a tumor, a liquid biopsy is performed through a simple blood draw. As a result, it can potentially be repeated more frequently and safely, causing minimal discomfort to patients. The blood sample is then analyzed in specialized laboratories using advanced technologies.
Several methods exist to capture CTCs. Some exploit physical properties, as tumor cells are often larger or shaped differently than normal blood cells. Others rely on biological markers, detecting proteins found on the surface of cancer cells but not on healthy cells.
Once captured, CTCs can be counted and further analyzed to reveal their biological characteristics. Unlike circulating tumor DNA (ctDNA), which consists of small DNA fragments released by tumor cells, CTCs are intact, living cells. This allows scientists to study not only their DNA but also their RNA, proteins, structure, and biological behavior.
What are the main challenges scientists face in identifying and analyzing these rare cells?
Although the idea of finding cancer cells in a blood sample may sound simple, detecting CTCs is extremely challenging.
The main challenges include:
• CTCs are extremely rare: a blood sample may contain billions of blood cells but only a handful of CTCs, making them difficult to find and isolate reliably. It is the ultimate scientific example of finding a needle in a haystack.
• CTCs are highly diverse: not all CTCs look alike or carry the same biological markers, and their characteristics can change as cancer evolves. As a result, some cells may escape detection, even with advanced technologies.
• CTCs are fragile: the process of isolating them from blood can sometimes damage them, making further analysis more difficult.
• CTCs are difficult to identify: scientists must use sophisticated detection tools, such as fluorescent antibodies that bind to tumor-specific proteins, to distinguish true cancer cells from the millions of normal cells circulating in the blood.
• CTCs are not released equally: some breast cancer metastases shed very few cells into the bloodstream, meaning a negative test does not necessarily indicate that the cancer is inactive.
What this means (and what it does not yet mean) for patients today?
CTC testing has shown considerable promise in metastatic breast cancer, but it is important to distinguish between what the technology can do today and what researchers hope it may do in the future.
Today, its main proven role is as a blood-based marker of disease activity and treatment response: higher CTC counts generally correlate with poorer prognosis and shorter survival. Repeated CTC measurements can provide a minimally invasive, real-time view of tumor evolution and may help identify patients at higher risk of progression who could benefit from closer monitoring. However, CTCs are not yet a routine decision-making tool. Major clinical guidelines (ASCO and ESMO) do not currently recommend using CTC counts alone to select or change treatments, and clinical trials evaluating CTC-guided therapy have produced mixed results or are still ongoing.
Future perspectives: how these technologies may support better monitoring and personalized care?
Although CTC testing is not yet part of routine clinical practice, the field of liquid biopsy is evolving rapidly and the long-term goal is to provide patients and clinicians with richer information using this minimally invasive blood test.
Researchers are working to improve the sensitivity and reliability of CTC detection so it can identify treatment resistance earlier, monitor therapy response more closely, detect recurrence before symptoms appear, and reveal biological features that may guide personalized treatment strategies.
As with any emerging technology, important questions remain. Yet each new discovery brings researchers closer to more informed, personalized cancer care and offers hope for the future.
If you have questions about CTCs or wonder whether this technology may be relevant to your care, talk to your oncology team. They can help you understand its potential benefits, limitations, and current role in clinical care.
Special thanks to Francesca Senic-Matuglia, PhD, Assay Development Biologist, at TETHIS for this content.
